Article
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Journal of cellular biochemistry - 1 Feb 2007
Moneo Victoria, Serelde Beatriz G, Fominaya Jesús, Leal Juan F M, Blanco-Aparicio Carmen, Romero Lourdes, Sánchez-Beato Margarita, Cigudosa Juan C, Tercero Juan C, Piris Miguel A, Jimeno Jose, Carnero Amancio
Abstract excerpt
Yondelis (Trabectedin, ET-743) is a marine anticancer agent currently in Phase II/III development in patients with advanced pretreated soft tissue sarcoma. In the present study, we generated a panel of low passaged tumor cell lines from samples explanted from chemonaive sarcoma patients with different tumor types. We assessed in vitro sensitivity/resistance to Trabectedin and doxorubicin in a panel of sarcoma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.